Cargando…

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands

In the past 20 years the Netherlands-based RACE trials have investigated important concepts in clinical atrial fibrillation (AF). Their scope ranged from rhythm versus rate control to early or delayed cardioversion and also included early comprehensive management of AF in two trials, one focusing on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crijns, H. J. G. M., Van Gelder, I. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940410/ https://www.ncbi.nlm.nih.gov/pubmed/32780325 http://dx.doi.org/10.1007/s12471-020-01476-0

Ejemplares similares

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
por: van de Lande, Martijn E, et al.
Publicado: (2023)

A Paradigm Shift in Risk Prediction in Patients With Atrial Fibrillation
por: Choi, Eue-Keun, et al.
Publicado: (2022)

Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study
por: Kloosterman, Mariëlle, et al.
Publicado: (2019)

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial
por: Koldenhof, T, et al.
Publicado: (2023)

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V
por: Park Frausing, M H J, et al.
Publicado: (2023)

Reappraisal of Atrial fibrillation: interaction between hyperCoagulability, Electrical remodelling and Vascular destabilisation in the progression of AF (RACE V) Tissue Bank Project: study design
por: Gilbers, M. D., et al.
Publicado: (2021)

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study
por: Van De Lande, M E, et al.
Publicado: (2023)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Newly discovered atrial fibrillation: who(se) care(s)?
por: Crijns, Harry J G M, et al.
Publicado: (2020)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021)

Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study
por: Nguyen, Bao Oanh, et al.
Publicado: (2020)

Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V
por: De With, Ruben R, et al.
Publicado: (2020)

Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies
por: De With, Ruben R, et al.
Publicado: (2021)

Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
por: Artola Arita, Vicente, et al.
Publicado: (2023)

Novel insights in pathophysiology of postoperative atrial fibrillation
por: Kharbanda, Rohit K., et al.
Publicado: (2021)

New concepts in atrial fibrillation pathophysiology
por: Hermans, Ben J. M., et al.
Publicado: (2022)

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure
por: Brandes, Axel, et al.
Publicado: (2020)

Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation
por: Al-Jazairi, M. I. H., et al.
Publicado: (2019)

Cardioversion strategy impacts quality of rate control during recurrences of atrial fibrillation
por: Van Der Velden, R, et al.
Publicado: (2023)

Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study
por: Alings, M., et al.
Publicado: (2013)

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation
por: Nguyen, Bao-Oanh, et al.
Publicado: (2023)

Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation
por: Van Noord, Trudeke, et al.
Publicado: (2005)

Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management
por: Koniari, Ioanna, et al.
Publicado: (2021)

The Association Between Rheumatoid Arthritis and Atrial Fibrillation: Epidemiology, Pathophysiology and Management
por: Qian, Yezhou, et al.
Publicado: (2023)

Contemporary management of patients with atrial fibrillation in the Netherlands and Belgium: a report from the EORP-AF long-term general registry
por: Erküner, Ö., et al.
Publicado: (2021)

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
por: Pisters, R., et al.
Publicado: (2018)

Role of neural modulation in the pathophysiology of atrial fibrillation
por: Male, Shailesh, et al.
Publicado: (2014)

Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure
por: Denham, Nathan C., et al.
Publicado: (2018)

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)

Novel Dual Therapy: A Paradigm Shift in Anticoagulation in Patients of Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Pradhan, Akshyaya, et al.
Publicado: (2020)

Update on management of atrial fibrillation in heart failure: a focus on ablation
por: Mulder, Bart A, et al.
Publicado: (2022)

Proteomic Analysis of Atrial Appendages Revealed the Pathophysiological Changes of Atrial Fibrillation
por: Liu, Ban, et al.
Publicado: (2020)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Left Atrial Appendage Management with the Watchman Device during Hybrid Ablation of Atrial Fibrillation
por: Vroomen, Mindy, et al.
Publicado: (2019)

Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment
por: Leopoulou, Marianna, et al.
Publicado: (2023)

Incidence and outcome of atrial fibrillation: diversity throughout Europe
por: Rienstra, Michiel, et al.
Publicado: (2021)

Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
por: Aliot, Etienne, et al.
Publicado: (2011)

COVID-19 HEART unveiling as atrial fibrillation: pathophysiology, management and future directions for research
por: Kanuri, Sri Harsha, et al.
Publicado: (2023)

Atrial fibrillation progression: another step in the RACE to full understanding
por: Capucci, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_418u6r73a96us5qlgltnfbviiu